The purpose of this study is to prospectively study the efficacy of low dose ketamine infusions in treating patients who are admitted to the hospital with a sickle cell pain crisis. Participants will be prospectively randomized in unblinded fashion in the first 12 to 24 hours of an inpatient admission for sickle cell pain crisis to receive pain management without ketamine infusion (Group A) versus pain management that includes low-dose ketamine infusion starting at 0.2mg/kg/h (Group B). The effect of this intervention on various pain management and healthcare utilization outcome measures will be recorded and analyzed to determine whether or not there is a measurable benefit of using ketamine infusions in this patient population.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
Pain management
Duke Hospital
Durham, North Carolina, United States
Percentage reduction in grand mean opioid consumption from 0 to 72 hours
Time frame: baseline, 72 hours
Percentage reduction in grand mean pain score using the 11-point visual analog scale
Using standard 11-point visual analog pain scale, ranging from 0 = no pain to 10 = worst pain imaginable.
Time frame: baseline, 72 hours
Time from inpatient admission to readiness for discharge
Time frame: Upon discharge from the hospital (an average of 1 week)
30-day hospital readmission rate
Time frame: 30 days from discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.